Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase
II
and phase
III
trials
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-09-10
DOI
10.1111/bjd.21867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IL‐4 and IL‐13 both contribute to the homeostasis of human conjunctival goblet cells in vitro
- (2022) Pernille M. Hansen et al. ALLERGY
- Atopic eczema in adulthood and mortality: UK population–based cohort study, 1998-2016
- (2021) Richard J. Silverwood et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis
- (2021) Joseph F. Merola et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Conjunctivitis in adult patients with moderate‐to‐severe atopic dermatitis: results from five tralokinumab clinical trials
- (2021) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
- (2020) Emma Guttman-Yassky et al. JAMA Dermatology
- Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study
- (2020) Catherine Droitcourt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis
- (2020) Jonathan I. Silverberg et al. JAMA Dermatology
- Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
- (2020) J.I. Silverberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
- (2020) A. Wollenberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study
- (2020) Maria C. Schneeweiss et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children
- (2020) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis
- (2019) Lam C. Tsoi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
- (2019) Lawrence F. Eichenfield et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the UK and the US
- (2019) L. Andersen et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparative Safety of Systemic Immuno-modulatory Medications in Adults with Atopic Dermatitis
- (2019) Maria C. Schneeweiss et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Characterising Treatment‐related Patient Needs in Atopic Eczema: Insights for Personalised Goal Orientation
- (2019) M. Augustin et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
- (2019) Melinda J. Gooderham et al. JAMA Dermatology
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cause-specific mortality in adults with atopic dermatitis
- (2018) Jacob P. Thyssen et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II
- (2018) A. Wollenberg et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
- (2018) Reynold A Panettieri et al. Lancet Respiratory Medicine
- Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
- (2018) William W. Busse et al. EUROPEAN RESPIRATORY JOURNAL
- Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
- (2017) Patrick M. Brunner et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
- (2017) B. Popovic et al. JOURNAL OF MOLECULAR BIOLOGY
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies
- (2017) Mark Boguniewicz et al. Journal of Allergy and Clinical Immunology-In Practice
- Atopic dermatitis
- (2016) Stephan Weidinger et al. LANCET
- Reporting cumulative proportion of subjects with an adverse event based on data from multiple studies
- (2010) Christy Chuang-Stein et al. PHARMACEUTICAL STATISTICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started